EUVIMEDScopri EUVIMED
Crossref

Probiotic VSL#3 alleviates intrahepatic cholestasis of pregnancy by upregulating farnesoid X receptor-fibroblast growth factor 15 through regulation of the gut microbiota

Zhihua Zeng, Hua Li, Weitao Yang, Li Li, Ping Ni, Qiuling Chen, Wenjuan Zhou, Jing Peng, Le Huang

Journal of Reproductive Immunology · 2025-12 · 172 · 104653

DOI: 10.1016/j.jri.2025.104653 ↗

At a glance

Journal article in Journal of Reproductive Immunology, 2025-12. Written by Zhihua Zeng and 8 co-authors. Institution: Department of Obstetrics, Changsha Hospital for Maternal & Child Health Care Affiliated to Hunan Normal University, Changsha, Hunan 410007, China. Major MEDLINE topics: Gastrointestinal Microbiome, Cholestasis, Intrahepatic, Fibroblast Growth Factors, Receptors, Cytoplasmic and Nuclear. Cited 5 times so far (Crossref); 45 references. Funded by: Natural Science Foundation of Hunan Province.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Intrahepatic cholestasis of pregnancy (ICP) poses significant risks to both maternal and fetal health, and treatment options remain limited. This study investigated the efficacy and underlying mechanisms of VSL#3 in alleviating ICP. Clinical fecal and blood samples were collected from 26 patients with ICP and 21 healthy pregnant women. The gut microbiota composition was analyzed using 16S rRNA sequencing. To further explore causality, we established a fecal microbiota transplantation-ICP mouse model using fecal samples from ICP patients, as well as an estrogen-induced ICP mouse model. Compared with healthy pregnant women, ICP patients exhibited a distinct gut microbiota profile, characterized by an increased abundance of Bacteroides and Alistipes. Serum FGF19 levels were significantly lower in ICP patients, showing a negative correlation with liver function markers, such as serum total bile acid (TBA), and a positive correlation with beneficial genera including Bifidobacterium, Ruminococcus, Blautia, Dorea, Eubacterium (hallii group) and Ruminococcus (torques group). VSL#3 treatment in mice alleviated ICP manifestations by improving liver histopathology, reducing TBA and alanine aminotransferase levels, increasing FGF15 concentrations, and enhancing fetal outcomes. These beneficial effects were abolished by co-administration of the FXR antagonist Z-guggulsterone, confirming the role of FXR signaling. In conclusion, VSL#3 alleviated ICP by modulating the gut microbiota to activate the FXR-FGF15 axis, thereby reducing bile acid synthesis and improving maternal and fetal outcomes.

Subjects

MeSH terms (MEDLINE)

Gastrointestinal MicrobiomeCholestasis, IntrahepaticFibroblast Growth FactorsReceptors, Cytoplasmic and NuclearPregnancy ComplicationsProbioticsFemalePregnancyAnimalsHumansMiceAdultDisease Models, AnimalFecal Microbiota TransplantationUp-RegulationBile Acids and SaltsLiverReceptor, Farnesoid X-Activated

Author keywords

Bile acidFGF15/19FXRGut microbiotaIntrahepatic cholestasis of pregnancyVSL#3

Substances

Fibroblast Growth FactorsReceptors, Cytoplasmic and NuclearBile Acids and SaltsReceptor, Farnesoid X-Activatedfibroblast growth factor 15, mouseFGF19 protein, human

Authors and institutions

  • Department of Obstetrics, Changsha Hospital for Maternal & Child Health Care Affiliated to Hunan Normal University, Changsha, Hunan 410007, China.
  • Department of Obstetrics, Changsha Hospital for Maternal & Child Health Care Affiliated to Hunan Normal University, Changsha, Hunan 410007, China. Electronic address: 15084990624@163.com.

Funding

  • Natural Science Foundation of Hunan Province

Cite

APA

Zeng, Z., Li, H., Yang, W., Li, L., Ni, P., Chen, Q., Zhou, W., Peng, J., & Huang, L. (2025). Probiotic VSL#3 alleviates intrahepatic cholestasis of pregnancy by upregulating farnesoid X receptor-fibroblast growth factor 15 through regulation of the gut microbiota. Journal of Reproductive Immunology, 172, 104653. https://doi.org/10.1016/j.jri.2025.104653

Vancouver

Zeng Z, Li H, Yang W, Li L, Ni P, Chen Q, et al. Probiotic VSL#3 alleviates intrahepatic cholestasis of pregnancy by upregulating farnesoid X receptor-fibroblast growth factor 15 through regulation of the gut microbiota. Journal of Reproductive Immunology. 2025;172:104653. doi:10.1016/j.jri.2025.104653

BibTeX
@article{Zeng2025,
  author = {Zeng, Zhihua and Li, Hua and Yang, Weitao and Li, Li and Ni, Ping and Chen, Qiuling and Zhou, Wenjuan and Peng, Jing and Huang, Le},
  title = {Probiotic VSL#3 alleviates intrahepatic cholestasis of pregnancy by upregulating farnesoid X receptor-fibroblast growth factor 15 through regulation of the gut microbiota},
  journal = {Journal of Reproductive Immunology},
  year = {2025},
  volume = {172},
  pages = {104653},
  doi = {10.1016/j.jri.2025.104653}
}
Start for free →